The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of cixutumumab in combination with temsirolimus in pediatric patients with recurrent or refractory sarcoma: A report from the Children’s Oncology Group.
Lars M. Wagner
No relevant relationships to disclose
Maryam Fouladi
No relevant relationships to disclose
Atif Ahmed
No relevant relationships to disclose
Mark D. Krailo
No relevant relationships to disclose
Brenda Weigel
No relevant relationships to disclose
Steven G. DuBois
No relevant relationships to disclose
Austin Doyle
No relevant relationships to disclose
Helen X. Chen
No relevant relationships to disclose
Susan Blaney
No relevant relationships to disclose